Molecular mechanism of the enhanced viral fitness contributed by secondary mutations in the hemagglutinin protein of oseltamivir resistant H1N1 influenza viruses: Modeling studies of antibody and receptor binding

Gene

Volumn 557, Issue 1, 2015, Pages 19-27

  Behera, Abhisek Kumar ^a   Basu, Sushmita ^a   Cherian, Sarah S ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Antibody and receptor docking; H1N1 influenza A; Hemagglutinin; Molecular dynamics simulations; Neuraminidase H274Y mutation; Oseltamivir resistance

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ RECEPTOR; OSELTAMIVIR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RECEPTOR; ANTIVIRUS AGENT; H1N1 VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; SIALIDASE;

ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; IMMUNE EVASION; INFLUENZA VIRUS A H1N1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; RECEPTOR BINDING; VIRUS IMMUNITY; VIRUS MUTATION; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MUTATION; REPRODUCTIVE FITNESS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ORTHOMYXOVIRIDAE;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIVIRAL AGENTS; BINDING SITES, ANTIBODY; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; GENETIC FITNESS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN;

EID: 84920192213     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.12.003     Document Type: Article

References (62)

1. Abed Y., Goyette N., Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 2004, 9:577-581.
2. Abed Y., Pizzorno A., Bouhy X., et al. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog. 2011, 7(12):e1002431. 10.1371/journal.ppat.1002431.
3. Arnold K., Bordoli L., Kopp J., et al. The SWISS-MODEL Workspace: a web-based environment for protein structure homology modeling. Bioinformatics 2006, 22:195-201.
4. Baker N.A., Sept D., Joseph S., et al. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(18):10037-10041.
5. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., et al. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81(8):3684-3690. 10.1063/1.448118.
6. Berman H.M., Henrick K., Nakamura H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 2003, 10(12):98. 10.1038/nsb1203-980.
7. Bloom J.D., Gong L.I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328:1272-1275. 10.1126/science.1187816.
8. Bloom J.D., Nayak J.S., Baltimore D. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 2011, 6(7):e22201. 10.1371/journal.pone.0022201.
9. Bouvier N.M., Rahmat S., Pica N. Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J. Virol. 2012, 86(13):7268-7279. 10.1128/JVI. 07242-12.
10. Brownlee G.G., Fodor E. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356(1416):1871-1876.
11. Caton A.J., Brownlee G.G., Yewdell J.W., et al. The antigenic structure of the influenza virus A/PR/8/34 HA (H1 subtype). Cell 1982, 31(12pt 1):417-427.
12. Chen R., Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 2002, 47:281-294. 10.1002/prot.10092.
13. Collins P.J., Haire L.F., Lin Y.P., et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009, 27:6317-6323.
14. Cox N.J., Subbarao K. Global epidemiology of influenza: past and present. Annu. Rev. Med. 2000, 51:407-421.
15. Das S.R., Hensley S.E., David A., et al. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc. Natl. Acad. Sci. 2011, 108(51):E1417-E1422. 10.1073/pnas.1108754108.
16. Emini E.A., Hughes J.V., Perlow D.S., et al. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 1985, 55(3):836-839.
17. Filikov A.V., Mohan V., Vickers T.A., et al. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. J. Comput. Aided Mol. Des. 2000, 14(6):593-610.
18. Gambaryan A.S., Tuzikov A.B., Piskarev V.E., et al. Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'-sialyl (N-acetyllactosamine). Virology 1997, 232(2):345-350.
19. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 2010, 285:28403-28409.
20. Gamblin S.J., Haire L.F., Russell R.J., et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004, 1838-1842.
21. Ginting T.E., Shinya K., Kyan Y., et al. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J. Virol. 2012, 86(1):121-127. 10.1128/JVI. 06085-11.
22. Guan Y., Vijaykrishna D., Bahl J., et al. The emergence of the pandemic influenza viruses. Protein Cell 2010, 1:9-13.
23. Gubareva L.V., Kaiser L., Matrosovich M.N., et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183:523-531.
24. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
25. Hay A.J., Daniels R., Lin Y.P., et al. Report, WHO Influenza Centre, London: Characteristics of Human Influenza AH1N1, AH3N2, and B Viruses Isolated September 2007 to February 2008 2008, World Health Organization, Geneva, Switzerland, (http://www.nimr.mrc.ac.uk/documents/about/interim_report_mar_2008.pdf).
26. Hensley S.E., Das S.R., Bailey A.L., et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009, 326(5953):734-736. 10.1126/science.1178258.
27. Herlocher M.L., Truscon R., Elias S., et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 2004, 190:1627-1630.
28. Ives J.A., Carr J.A., Mendel D.B. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 2002, 55:307-3017.
29. Jackson D.C., Murray J.M., White D.O., et al. Enumeration of antigenic sites of influenza virus hemagglutinin. Infect. Immun. 1982, 37(3):912-918.
30. Jones G., Willett P., Glen R.C., et al. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267(3):727-748.
31. Jongkon N., Mokmak W., Chuakheaw D., et al. Prediction of avian influenza A binding preference to human receptor using conformational analysis of receptor bound to hemagglutinin. BMC Genomics 2009, 3. 10.1186/1471-2164-10-S3-S24.
32. Kim C.U., Lew W., William M.A., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogue with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119:681-690.
33. Kobasa D., Kodihalli S., Luo M., et al. Amino acid residues contributing to substrate specificity of influenza A virus NA. J. Virol. 1999, 73(8):6743-6751.
34. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276(1-2):172-174.
35. Krieger E., Darden T., Nabuurs S.B., et al. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 2004, 57(4):678-683.
36. Kumar S., Nussinov R. Close-range electrostatic interactions in proteins. Chembiochem 2002, 2;3(7):604-617. (Jul).
37. Matrosovich M., Zhou N., Kawaoka Y., et al. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J. Virol. 1999, 73(2):1146-1155.
38. Meijer A., Lackenby A., Hungnes O., et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 552-60. 10.3201/eid1504.181280.
39. Moscona A. Neuraminidsae inhibitors for Influenza. N. Engl. J. Med. 2005, 353(13):1363-1373.
40. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360:953-956.
41. Myers J.L., Wetzel K.S., Linderman S.L., et al. Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses. J. Virol. 2013, 87(20):11168-11172.
42. Ohuchi M., Ohuchi R., Feldmann A., et al. Regulation of receptor binding affinity of influenza virus HA by its carbohydrate moiety. J. Virol. 1997, 71(11):8377-8384.
43. Parker J.M., Guo D., Hodges R.S. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986, 25(19):5425-5432.
44. Pettersen E.F., Goddard T.D., Huang C.C., et al. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25(13):1605-1612.
45. Pierce B.G., Hourai Y., Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One 2011, 6(9):e24657.
46. Pruitt K.D., Tatusova T., Maglott D.R. NCBI reference sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucl. Acids Res. 2005, 33:D501-D504.
47. Rameix-Welti M.A., Enouf V., Cuvelier F., et al. Enzymatic properties of the neuraminidase of seasonal influenza H1N1 viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008, 4:e1000103. 10.1371/journal.ppat.1000103.
48. Rogers G.N., D'Souza B.L. Receptor binding properties of human and animal H1 influenza virus isolates. Virology 1989, 1:317-322.
49. Russell R.J., Haire L.F., Stevens D.J., et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443(7107):45-49.
50. Schwede T., Kopp J., Guex N., et al. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003, 31:3381-3385.
51. Stevens J., Blixt O., Tumpey T.M., et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006, 312(5772):404-410.
52. Takemoto D.K., Skehel J.J., Wiley D.C. A surface plasmon resonance assay for the binding of influenza virus hemagglutinin to its sialic acid receptor. Virology 1996, 217:452-458.
53. Verdonk M.L., Cole J.C., Hartshorn M.J., et al. Improved protein-ligand docking using GOLD. Proteins 2003, 52(4):609-623.
54. Wagner R., Matrosovich M., Klenk H.D. Functional balance between HA and NA in influenza virus infections. Rev. Med. Virol. 2002, 12(3):159-166.
55. Wallace A.C., Laskowski R.A., Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8(2):127-134.
56. Wang R., Lu Y., Fang X., et al. An extensive test of 14 scoring functions using the PDB bind refined set of 800 protein-ligand complexes. J. Chem. Inf. Comput. Sci. 2004, 44(6):2114-2125.
57. Whittle J.R., Zhang R., Khurana S., et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(34):14216-142121. 10.1073/pnas.1111497108.
58. WHO 2008/2009 Influenza A(H1N1) Virus Resistance to Oseltamivir - 2008/2009 Influenza Season, Northern Hemisphere, 18 March 2009 2009, World Health Organization, Geneva, (http://www.who.int/influenza/resources/documents/H1N1webupdate20090318_ed_ns.pdf. Accessed 24 November 2014).
59. WHO Pharmacological Management of Pandemic Influenza A (H1N1) 2009 (Accessed 25 November 2014). http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
60. Xu R., McBride R., Nycholat C.M., et al. Structural characterization of the hemagglutinin receptor specificity from the 2009 H1N1 influenza pandemic. J. Virol. 2012, 86(2):982-990. 10.1128/JVI. 06322-11.
61. Yang J.R., Lin Y.C., Huang Y.P., et al. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. PLoS One 2011, 6(3):e18177. 10.1371/journal.pone.0018177.
62. Zaraket H., Saito R., Suzuki Y., et al. Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. J. Clin. Microbiol. 2010, 48(4):1085-1092. 10.1128/JCM. 01532-09.